Fig. 3From: Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapyHemoglobin recovery in patients who did not achieve CR. a Percentage of patients with durable (≥ 2 consecutive visits) recovery at any time on study. b Percentage of patients with hemoglobin recovery after the first, second, and third treatment cycles. For treatment cycle analysis, one threshold measurement was required; all patients were included regardless of their BL levels but each cycle only included remaining patients at risk in that cycle. Analysis set, N = number of patients with hemoglobin results in the cycle; patients, n = number of patients meeting recovery criteria in the cycle. Abbreviations: BL, baseline; CR, complete remission; LDAC, low-dose cytarabineBack to article page